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BACKGROUND
In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemes-
tane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly 
lower among premenopausal women who received the aromatase inhibitor exemes-
tane plus ovarian suppression than among those who received tamoxifen plus ovarian 
suppression. The addition of ovarian suppression to tamoxifen did not result in sig-
nificantly lower recurrence rates than those with tamoxifen alone. Here, we report the 
updated results from the two trials.
METHODS
Premenopausal women were randomly assigned to receive 5 years of tamoxifen, 
tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT 
and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppres-
sion in TEXT. Randomization was stratified according to the receipt of chemotherapy.
RESULTS
In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% 
with tamoxifen plus ovarian suppression, and 85.9% with exemestane plus ovarian 
suppression (P = 0.009 for tamoxifen alone vs. tamoxifen plus ovarian suppression). 
The 8-year rate of overall survival was 91.5% with tamoxifen alone, 93.3% with 
tamoxifen plus ovarian suppression, and 92.1% with exemestane plus ovarian sup-
pression (P = 0.01 for tamoxifen alone vs. tamoxifen plus ovarian suppression); among 
the women who remained premenopausal after chemotherapy, the rates were 85.1%, 
89.4%, and 87.2%, respectively. Among the women with cancers that were negative 
for HER2 who received chemotherapy, the 8-year rate of distant recurrence with 
exemestane plus ovarian suppression was lower than the rate with tamoxifen plus 
ovarian suppression (by 7.0 percentage points in SOFT and by 5.0 percentage points in 
TEXT). Grade 3 or higher adverse events were reported in 24.6% of the tamoxifen-
alone group, 31.0% of the tamoxifen–ovarian suppression group, and 32.3% of the 
exemestane–ovarian suppression group.
CONCLUSIONS
Among premenopausal women with breast cancer, the addition of ovarian suppres-
sion to tamoxifen resulted in significantly higher 8-year rates of both disease-free and 
overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression 
resulted in even higher rates of freedom from recurrence. The frequency of adverse 
events was higher in the two groups that received ovarian suppression than in the 
tamoxifen-alone group. (Funded by Pfizer and others; SOFT and TEXT ClinicalTrials 
.gov numbers, NCT00066690 and NCT00066703, respectively.)
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A djuvant treatment with tamoxi-fen for 5 years reduces the recurrence of premenopausal estrogen-receptor–positive 
breast cancer, with increasing benefits for over-
all survival during 5 to 15 years of follow-up.1 
Extending the duration of tamoxifen treatment 
to 10 years further improves outcomes.2 The ef-
fect of adding ovarian suppression has been less 
certain.3 Among women with estrogen-receptor–
positive tumors, those who are under the age of 
35 years (who usually retain ovarian estrogen pro-
duction despite chemotherapy) have a higher risk 
of recurrence than those who are 35 years of age 
or older.4,5
In 2003, the International Breast Cancer Study 
Group initiated two randomized trials, the Sup-
pression of Ovarian Function Trial (SOFT) and the 
Tamoxifen and Exemestane Trial (TEXT), involving 
premenopausal women with hormone-receptor–
positive early breast cancer. SOFT was designed to 
determine the value of adding ovarian suppres-
sion to tamoxifen and to determine the role of the 
aromatase inhibitor exemestane plus ovarian sup-
pression. TEXT was designed to determine the 
value of exemestane as compared with tamoxi-
fen in women treated with ovarian suppression.
After a median follow-up of 5.6 years, the 
primary results of SOFT did not show a signifi-
cantly higher rate of disease-free survival with 
the addition of ovarian suppression to tamoxifen 
than with tamoxifen alone, although the addition 
of ovarian suppression reduced recurrence rates 
among women at increased risk for recurrence 
who received adjuvant chemotherapy.6 Results of 
the combined analysis of SOFT and TEXT after a 
median follow-up of 5.7 years showed that exemes-
tane plus ovarian suppression resulted in signifi-
cantly higher rates of disease-free survival than the 
rates with tamoxifen plus ovarian suppression.7 
Here, we report results of a prespecified updated 
analysis of SOFT and the combined analysis of 
data from SOFT and TEXT8 after a median follow-
up of 8 and 9 years, respectively. We also report on 
the subgroup of women with cancers that were 
negative for human epidermal growth factor re-
ceptor 2 (HER2), who made up the majority of 
patients enrolled in the two trials.
Me thods
Patients
The trial designs and eligibility criteria in SOFT 
and TEXT have been described previously.6-8 The 
two trials included women with documented pre-
menopausal status and operable breast cancer that 
expressed estrogen or progesterone receptors in at 
least 10% of cells. The use of chemotherapy was 
optional. All the patients who were enrolled in 
TEXT underwent randomization within 12 weeks 
after definitive surgery, and if chemotherapy was 
received, it was initiated concurrently with ovar-
ian suppression after randomization. The patients 
in SOFT who did not receive chemotherapy also 
underwent randomization within 12 weeks after 
definitive surgery. The patients in SOFT who 
received chemotherapy had received it previously, 
remained premenopausal, and underwent ran-
domization within 8 months after completing 
chemotherapy, once a premenopausal estradiol 
level had been confirmed by a local laboratory.
Trial Designs
Women who were enrolled in SOFT were ran-
domly assigned in a 1:1:1 ratio to receive tamoxifen 
at a dose of 20 mg daily, tamoxifen plus ovarian 
suppression, or exemestane at a dose of 25 mg 
daily plus ovarian suppression. Treatment was to 
be administered for 5 years from randomization. 
Ovarian suppression was achieved by a choice of 
triptorelin at a dose of 3.75 mg by intramuscular 
injection every 28 days, bilateral oophorectomy, or 
ovarian irradiation.6 Patients receiving triptorelin 
could subsequently undergo oophorectomy or ir-
radiation. Randomization was stratified according 
to receipt of previous chemotherapy, lymph-node 
status, and intended initial ovarian suppression 
method, if assigned.
Women who were enrolled in TEXT were ran-
domly assigned in a 1:1 ratio to receive exemestane 
plus triptorelin or tamoxifen plus triptorelin for 
5 years after randomization. Bilateral oophorec-
tomy or ovarian irradiation was allowed after at 
least 6 months of receipt of triptorelin. Random-
ization was stratified according to the intended 
use of adjuvant chemotherapy and lymph-node 
status. The assessment of patients and recording 
of adverse events followed a regular schedule. 
(Details regarding the assessments are provided 
in the trial protocol and in the Supplementary Ap-
pendix, both available with the full text of this 
article at NEJM.org.)
Primary and Secondary End Points
In the two trials, the primary end point in the 
time-to-event analysis was disease-free survival, 
which was defined as survival free of the first oc-
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currence of one of the following: invasive recur-
rence of breast cancer (local, regional, or distant), 
invasive contralateral breast cancer, a second (non-
breast) invasive cancer, or death without recurrence 
or a second cancer. Key secondary end points were 
the interval without breast cancer (defined as the 
time from randomization to the recurrence of lo-
cal, regional, or distant invasive breast cancer or 
invasive contralateral breast cancer), the interval 
from randomization to the recurrence of breast 
cancer at a distant site, and overall survival, which 
was defined as the time from randomization until 
death from any cause.
Adverse Events
We systematically queried for 22 targeted adverse 
events and collected other adverse events of grade 
3 or higher using the Common Terminology Crite-
ria for Adverse Events, version 3.0.9 The assessment 
of patients and systematic recording of the 22 tar-
geted adverse events followed a regular schedule.
Trial Oversight
SOFT and TEXT were coordinated by the Inter-
national Breast Cancer Study Group, which was 
responsible for the trial designs, data collection, 
management, and analysis. The ethics committee 
at each participating center approved the trial pro-
tocol, and all the patients provided written in-
formed consent. Pfizer and Ipsen, the respective 
manufacturers of exemestane and triptorelin, do-
nated the drugs used in the trials; neither company 
had any role in the conduct of the trials or in the 
analyses of the data. The tamoxifen that was used 
in the trials was provided by prescription. The 
manuscript was written solely by the authors, who 
vouch for the data and analyses reported and fidel-
ity of the trials to the protocols. The steering com-
mittee (which included employees of Pfizer and 
Ipsen) reviewed the manuscript and made the de-
cision to submit it for publication.
Statistical Analysis
The original and amended statistical analysis plans 
for SOFT and TEXT have been described previ-
ously.8 The test for the superiority of tamoxifen 
plus ovarian suppression over tamoxifen alone was 
the primary analysis in SOFT (calculated with a 
two-sided alpha level of 0.05), and the comparison 
between exemestane plus ovarian suppression and 
tamoxifen alone was a secondary objective (cal-
culated as an estimate and 95% confidence inter-
val, without a statistical test).6 An analysis of the 
combined data from SOFT and TEXT was per-
formed to compare exemestane plus ovarian sup-
pression with tamoxifen plus ovarian suppression 
with a two-sided alpha level of 0.05.7
Analyses were performed according to the 
intention-to-treat principle, with the calculation 
of Kaplan–Meier estimates of time-to-event end 
points. In SOFT, we used stratified log-rank tests 
to compare tamoxifen plus ovarian suppression 
with tamoxifen alone, with stratification accord-
ing to receipt or nonreceipt of previous chemo-
therapy and lymph-node status. In the combined 
analysis of data from SOFT and TEXT, we com-
pared exemestane plus ovarian suppression with 
tamoxifen plus ovarian suppression, with strati-
fication according to trial, receipt or nonreceipt 
of chemotherapy, and lymph-node status. We used 
stratified Cox proportional-hazards regression to 
estimate hazard ratios and 95% confidence inter-
vals. The heterogeneity of the treatment effect ac-
cording to subgroup was investigated by means of 
tests of treatment–covariate interaction; P values 
for these tests were not adjusted for multiple com-
parisons. Analyses that focused on the HER2-
negative population include estimates and 95% 
confidence intervals, which were not adjusted for 
multiple comparisons, so inferences should be 
viewed as preliminary.
R esult s
Patients
From December 2003 through January 2011, we 
randomly assigned 1021 premenopausal women 
to receive tamoxifen alone, 1024 to receive tamox-
ifen plus ovarian suppression, and 1021 to receive 
exemestane plus ovarian suppression in SOFT. 
After exclusions, 3047 women were included in 
the intention-to-treat population for the two pair-
wise comparisons of tamoxifen alone versus 
tamoxifen plus ovarian suppression and exemes-
tane plus ovarian suppression (Fig. 1, and Fig. S1 
in the Supplementary Appendix). A total of 1628 
patients (53.4%) had received chemotherapy be-
fore randomization (Table 1). The median age of 
the patients who had received chemotherapy was 
40 years, as compared with a median age of 46 
years among those who had not received chemo-
therapy. Node-positive disease was present in 
34.5% of the patients. The majority of the patients 
(84.9%) had HER2-negative tumors.
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From November 2003 through April 2011, we 
randomly assigned 1338 premenopausal women 
to receive exemestane plus ovarian suppression 
and 1334 to receive tamoxifen plus ovarian sup-
pression in TEXT. After exclusions, 2660 women 
were included in the intention-to-treat population. 
A total of 1607 patients (60.4%) received chemo-
therapy after randomization (Table 1). After ex-
clusions, 4690 women were included in the com-
bined SOFT and TEXT intention-to-treat population 
for the comparison between exemestane plus 
ovarian suppression and tamoxifen plus ovarian 
suppression (Fig. 1, and Fig. S5 in the Supple-
mentary Appendix). HER2-negative disease was 
present in 86.0% of the patients in the combined 
population.
For the updated analyses, 87.5% of all the pa-
tients in SOFT and TEXT had clinical follow-up 
data, and 4.4% had national registry–based fol-
low-up only. The numbers of patients who with-
drew consent or were lost to follow-up were similar 
across the treatment groups (Figs. S1 and S5 in 
the Supplementary Appendix).
Efficacy of Ovarian Suppression in SOFT
After a median follow-up of 8 years, the 8-year 
rate of disease-free survival was 83.2% among 
patients assigned to receive tamoxifen plus ovar-
ian suppression and 78.9% among those assigned 
to receive tamoxifen alone (hazard ratio for recur-
rence, a second invasive cancer, or death, 0.76; 95% 
confidence interval [CI], 0.62 to 0.93; P = 0.009), for 
a difference of 4.2 percentage points (Fig. 2A, and 
Table S1 in the Supplementary Appendix). Among 
the patients who were assigned to receive exemes-
tane plus ovarian suppression, the rate of disease-
free survival was 85.9%, a difference of 7.0 per-
centage points over tamoxifen alone (hazard ratio, 
0.65; 95% CI, 0.53 to 0.81) (Fig. 2A). Of 518 first 
events, 279 (53.9%) involved distant sites, 51 (9.8%) 
were invasive contralateral breast cancers, 105 
(20.3%) involved locoregional sites, and the re-
maining 83 events (16.0%) involved second (non-
breast) cancers or deaths from other causes (Table 
S2 in the Supplementary Appendix). No evidence 
of heterogeneity of relative treatment effect accord-
ing to previous receipt or nonreceipt of chemo-
Figure 1. Randomization and Analyses in SOFT and TEXT.
SOFT denotes Suppression of Ovarian Function Trial, and TEXT Tamoxifen and Exemestane Trial.
5738 Patients underwent randomization
Tamoxifen alone
Tamoxifen
plus ovarian
suppression
Tamoxifen
plus ovarian
suppression
Exemestane
plus ovarian
suppression
Exemestane
plus ovarian
suppression
3066 Underwent randomization in SOFT
and were stratified according to nonreceipt
of chemotherapy or receipt
before randomization
2672 Underwent randomization in TEXT
and were stratified according to nonreceipt
of chemotherapy or receipt
during the trial
In SOFT and TEXT combined, efficacy
of exemestane plus ovarian suppression vs.
tamoxifen plus ovarian suppression
Efficacy of ovarian suppression in SOFT
Primary analysis: tamoxifen plus
ovarian suppression vs.
tamoxifen alone
Secondary analysis: exemestane plus
ovarian suppression vs.
tamoxifen alone
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therapy was noted (Fig. 2B and 2C). Recurrences 
were more frequent in the patients who had re-
ceived chemotherapy, with an 8-year rate of dis-
ease-free survival in this cohort of 71.4% among 
patients assigned to receive tamoxifen alone, 76.7% 
among those assigned to receive tamoxifen plus 
ovarian suppression, and 80.4% among those 
assigned to receive exemestane plus ovarian sup-
pression, differences as compared with tamoxi-
fen alone of 5.3 and 9.0 percentage points, respec-
tively (Fig. 2C).
In subgroup analyses, the only notable hetero-
geneity of treatment effect was according to HER2 
status (Fig. S2A in the Supplementary Appendix). 
The results suggested a greater benefit from the 
Figure 2 (facing page). Kaplan–Meier Estimates  
of Disease-free Survival after a Median Follow-up  
of 8 Years in SOFT.
Shown are Kaplan–Meier estimates of the rates of dis‑
ease‑free survival in SOFT according to treatment as‑
signment — tamoxifen alone (T), tamoxifen plus ovar‑
ian suppression (T–OS), or exemestane plus ovarian 
suppression (E–OS) — among all the patients in the 
trial (Panel A) and according to chemotherapy status 
(Panels B and C). In Panel A, tamoxifen plus ovarian 
suppression resulted in a 24% lower relative risk of  
recurrence, a second invasive cancer, or death than 
tamoxifen alone (P = 0.009). In each panel, the 8‑year 
data are highlighted by a black vertical line. The haz‑
ard ratios are for disease recurrence, a second invasive 
cancer, or death.
Characteristic SOFT TEXT
No Chemotherapy 
(N = 1419)
Chemotherapy 
(N = 1628)†
No Chemotherapy 
(N = 1053)
Chemotherapy 
(N = 1607)†
Median age — yr 46 40 45 43
Age group — no. (%)
<35 yr 21 (1.5) 329 (20.2) 41 (3.9) 191 (11.9)
35–39 yr 110 (7.8) 473 (29.1) 123 (11.7) 289 (18.0)
40–49 yr 1045 (73.6) 772 (47.4) 768 (72.9) 1047 (65.2)
≥50 yr 243 (17.1) 54 (3.3) 121 (11.5) 80 (5.0)
Lymph‑node status — no. (%)
Negative 1294 (91.2) 701 (43.1) 835 (79.3) 542 (33.7)
Positive 125 (8.8) 927 (56.9) 218 (20.7) 1065 (66.3)
Tumor size — no. (%)
≤2 cm 1213 (85.5) 800 (49.1) 846 (80.3) 738 (45.9)
>2 cm 199 (14.0) 764 (46.9) 204 (19.3) 846 (52.6)
Unknown 7 (0.5) 64 (3.9) 3 (0.3) 23 (1.4)
HER2 status — no. (%)‡
Negative 1329 (93.7) 1257 (77.2) 991 (94.1) 1317 (82.0)
Positive 53 (3.7) 313 (19.2) 53 (5.0) 276 (17.2)
Unknown or not assessed 37 (2.6) 58 (3.6) 9 (0.9) 14 (0.9)
Median interval from surgery to randomization 
(IQR) — mo
1.8 (1.2–2.4) 8.0 (5.7–10.3) 1.5 (1.1–1.9) 1.2 (0.9–1.6)
*  Percentages may not total 100 because of rounding. HER2 denotes human epidermal growth factor receptor 2, IQR interquartile range, 
SOFT Suppression of Ovarian Function Trial, and TEXT Tamoxifen and Exemestane Trial.
†  Among patients who received chemotherapy, patients in SOFT had received chemotherapy before randomization and those in TEXT re‑
ceived chemotherapy during the trial concurrently with ovarian suppression.
‡  Among the patients with HER2‑positive disease, HER2‑directed therapy was administered to 220 of 366 patients (60.1%) in SOFT (including 
3 patients who did not receive chemotherapy and 217 patients who had received chemotherapy previously) and to 156 of 329 patients 
(47.4%) in TEXT (including 9 patients who did not receive chemotherapy and 147 patients who received chemotherapy).
Table 1. Characteristics of the Patients in SOFT and TEXT at Baseline, According to Chemotherapy Status.*
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addition of ovarian suppression to tamoxifen, as 
compared with tamoxifen alone, among women 
with HER2-positive disease (hazard ratio for re-
currence, a second invasive cancer, or death, 0.41; 
95% CI, 0.22 to 0.75) than among those with 
HER2-negative disease (hazard ratio, 0.83; 95% 
CI, 0.67 to 1.04; P = 0.04 for interaction) (Fig. 3). 
The estimates of relative treatment effect with 
exemestane plus ovarian suppression as compared 
with tamoxifen alone were similar for HER2-posi-
tive and HER2-negative disease (P = 0.44 for in-
teraction) (Fig. 3, and Fig. S2B in the Supplemen-
tary Appendix). Among the patients who received 
chemotherapy for HER2-negative tumors, the rate 
of disease-free survival at 8 years was 71.9% 
among the patients assigned to receive tamoxifen 
alone, 73.9% among those assigned to receive 
tamoxifen plus ovarian suppression, and 83.1% 
among those assigned to receive exemestane plus 
ovarian suppression, differences of 2.0 and 11.2 
percentage points, respectively, as compared with 
tamoxifen alone.
Recurrence of breast cancer at a distant site 
was reported in 306 of 3047 patients (10.0%) in 
SOFT. The addition of ovarian suppression to 
tamoxifen did not result in a significantly lower 
Figure 3. Disease-free Survival among All Patients and According to HER2 and Chemotherapy Status in SOFT.
Shown are hazard ratios and estimates of 8‑year disease‑free survival in SOFT comparing patients who received tamoxifen alone with 
those who received tamoxifen plus ovarian suppression (Panel A) and those who received exemestane plus ovarian suppression (Panel B), 
according to status with respect to HER2 (human epidermal growth factor receptor 2) and receipt of chemotherapy. The hazard ratios 
are for disease recurrence, a second invasive cancer, or death. In the comparison involving patients receiving tamoxifen plus ovarian 
suppression, there was significant interaction according to HER2 status (P = 0.04), but the interaction was not significant in the compar‑
ison involving those receiving exemestane plus ovarian suppression (P = 0.44). The 8‑year values for disease‑free survival are based on 
Kaplan–Meier estimates. The solid vertical lines at 0.76 in Panel A and at 0.65 in Panel B indicate the overall hazard‑ratio estimates for 
the two comparisons. The comparisons for patients with HER2‑positive disease are not presented according to receipt or nonreceipt of 
chemotherapy because the majority of these patients (86%) had received chemotherapy. Among the patients with HER2‑negative dis‑
ease, testing was not performed for interaction with chemotherapy status. Data are not shown for 95 patients with unknown HER2 sta‑
tus. The x axis is scaled according to the natural logarithm of the hazard ratio. The size of the squares is inversely proportional to the 
standard error of the hazard ratio.
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rate of distant recurrence than that with tamox-
ifen alone (hazard ratio for recurrence, 0.86; 95% 
CI, 0.66 to 1.13; P = 0.28). The rate of distant re-
currence was lower among patients assigned to 
receive exemestane plus ovarian suppression 
than among those assigned to receive tamoxifen 
alone (hazard ratio, 0.73; 95% CI, 0.55 to 0.96) 
(Fig. 4A). Most distant recurrences occurred in 
patients who had received chemotherapy (Fig. 4C). 
The 8-year rate of freedom from distant recur-
rence in this cohort was 80.0% among patients 
assigned to receive tamoxifen alone, 82.1% among 
those assigned to receive tamoxifen plus ovarian 
suppression, and 84.5% among those assigned 
to receive exemestane plus ovarian suppression. 
Among patients who received chemotherapy for 
Figure 4. Kaplan–Meier Estimates of Freedom from Distant Recurrence and of Overall Survival in SOFT.
Shown are estimates of rates of freedom from distant recurrence and of overall survival after a median follow‑up of 8 years in SOFT 
among all the patients in the trial (Panels A and B, respectively) and among those who had received chemotherapy before randomiza‑
tion (Panels C and D, respectively). The addition of ovarian suppression to tamoxifen did not result in a significantly lower rate of distant 
recurrence than that with tamoxifen alone (P = 0.28), but the rate of overall survival was significantly higher (P = 0.01). In Panels A and C, 
the hazard ratios are for recurrence of breast cancer at a distant site; the hazard ratios in Panels B and D are for death. The 8‑year values 
are based on Kaplan–Meier estimates of the time to an event. The estimates for patients who did not receive chemotherapy are provid‑
ed in Figure S3B in the Supplementary Appendix; the rates were more than 97% in each treatment group for both end points.
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HER2-negative tumors, the 8-year rate of free-
dom from distant recurrence was 80.8% among 
patients assigned to receive tamoxifen alone, 79.8% 
among those assigned to receive tamoxifen plus 
ovarian suppression, and 86.8% among those as-
signed to receive exemestane plus ovarian sup-
pression.
Death was reported in 225 patients (7.4%), and 
9 deaths occurred without a preceding cancer-
associated event (Tables S2C and S3 in the Sup-
plementary Appendix). The rate of overall survival 
in SOFT at 8 years was significantly higher with 
tamoxifen plus ovarian suppression (93.3%; 
95% CI, 91.4 to 94.8) than with tamoxifen alone 
(91.5%; 95% CI, 89.4 to 93.2) (hazard ratio for 
death, 0.67; 95% CI, 0.48 to 0.92; P = 0.01) (Fig. 4B). 
The rate of overall survival among patients as-
signed to receive exemestane plus ovarian sup-
pression was 92.1% (95% CI, 90.0 to 93.7) (haz-
ard ratio for death vs. tamoxifen, 0.85; 95% CI, 
0.62 to 1.15). Most deaths occurred in patients 
who had received chemotherapy. The rate of 
overall survival at 8 years in the chemotherapy 
cohort was 89.4% among patients assigned to 
receive tamoxifen plus ovarian suppression and 
85.1% among those assigned to receive tamoxi-
fen alone (hazard ratio for death, 0.59; 95% CI, 
0.42 to 0.84). In this cohort, the rate of overall 
survival among those assigned to receive exemes-
tane plus ovarian suppression was 87.2% (hazard 
ratio for death vs. tamoxifen, 0.79; 95% CI, 0.57 
to 1.09) (Fig. 4D). Among the patients who had 
received previous chemotherapy for HER2-nega-
tive tumors, the 8-year overall survival rate was 
85.2% among patients assigned to receive tamox-
ifen alone, 87.7% among those assigned to re-
ceive tamoxifen plus ovarian suppression (haz-
ard ratio for death vs. tamoxifen, 0.70; 95% CI, 
0.48 to 1.02), and 88.7% among those assigned 
to receive exemestane plus ovarian suppression 
(hazard ratio for death vs. tamoxifen, 0.71; 95% CI, 
0.49 to 1.05).
Among patients in SOFT who did not receive 
chemotherapy, 23.2% of the first disease-free 
survival events were contralateral breast cancers 
(Table S2 in the Supplementary Appendix). The 
8-year rate of freedom from breast cancer in this 
cohort was 91.4% (95% CI, 87.8 to 94.0) among 
patients assigned to receive tamoxifen alone, 93.6% 
(95% CI, 90.9 to 95.6) among those assigned to 
receive tamoxifen plus ovarian suppression, and 
95.4% (95% CI, 92.8 to 97.1) among those assigned 
to receive exemestane plus ovarian suppression 
(Fig. S3A in the Supplementary Appendix). There 
were 26 distant recurrences; 12 of 24 deaths in 
this cohort (50%) occurred in the absence of dis-
tant recurrence, with more than 97% of the pa-
tients free of distant recurrence and alive in each 
treatment group at 8 years (Table S3 and Fig. 
S3B in the Supplementary Appendix).
Efficacy of Exemestane or Tamoxifen  
with Ovarian Suppression
After a median follow-up of 9 years of the 4690 
patients in the combined population enrolled in 
TEXT and SOFT whose protocol-assigned thera-
py included ovarian suppression (Fig. 1, and Fig. 
S5 in the Supplementary Appendix), 720 patients 
(15.4%) had disease recurrence, had a second 
invasive cancer, or had died. The 8-year disease-
free survival rate was 86.8% among patients as-
signed to receive exemestane plus ovarian sup-
pression and 82.8% among those assigned to 
receive tamoxifen plus ovarian suppression, a dif-
ference of 4.0 percentage points (hazard ratio 
for recurrence, a second invasive cancer, or death, 
0.77; 95% CI, 0.67 to 0.90; P<0.001) (Fig. 5A, and 
Table S5 in the Supplementary Appendix). In sub-
group analyses, the only heterogeneity of treat-
ment effect was according to HER2 status (Fig. S6 
in the Supplementary Appendix). Among the pa-
tients with HER2-negative tumors, the 8-year dis-
ease-free survival rate was 88.1% among patients 
assigned to receive exemestane plus ovarian sup-
pression and 82.7% among those assigned to re-
ceive tamoxifen plus ovarian suppression, a differ-
ence of 5.4 percentage points (hazard ratio, 0.70; 
95% CI, 0.60 to 0.83) (Fig. 6).
The recurrence of breast cancer at a distant site 
was reported in 433 patients (9.2%). The 8-year 
rate of freedom from distant recurrence was 91.8% 
among patients assigned to receive exemestane 
plus ovarian suppression and 89.7% among those 
assigned to receive tamoxifen plus ovarian sup-
pression, a difference of 2.1 percentage points 
(hazard ratio for recurrence, 0.80; 95% CI, 0.66 
to 0.96; P = 0.02) (Fig. 5B). Among patients with 
HER2-negative tumors, the 8-year rate of free-
dom from distant recurrence was 93.0% among 
patients assigned to receive exemestane plus ovar-
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ian suppression and 89.6% among those assigned 
to receive tamoxifen plus ovarian suppression, a 
difference of 3.5 percentage points (hazard ratio 
for recurrence, 0.69; 95% CI, 0.56 to 0.85) (Fig. 6). 
The majority of distant recurrences (87.8%) oc-
curred among patients who had received chemo-
therapy (Fig. S7B in the Supplementary Appendix). 
In the combined population, more than 96% of the 
patients who did not receive chemotherapy were 
free from distant recurrence at 8 years in each 
treatment group (Fig. S7C in the Supplementary 
Appendix). In the HER2-negative chemotherapy 
cohorts, the 8-year rate of freedom from distant 
recurrence was higher among those assigned to 
receive exemestane plus ovarian suppression than 
among those assigned to receive tamoxifen plus 
ovarian suppression (by 7.0 percentage points in 
SOFT and 5.0 percentage points in TEXT) (Fig. 6).
In the combined analysis, 320 patients (6.8%) 
had died after a median follow-up of 9 years. 
The rate of overall survival at 8 years was 93.4% 
among patients assigned to receive exemestane 
plus ovarian suppression and 93.3% among those 
assigned to receive tamoxifen plus ovarian sup-
pression (hazard ratio for death, 0.98; 95% CI, 
0.79 to 1.22; P = 0.84) (Fig. 5C); among those with 
HER2-negative tumors, the corresponding rates 
were 94.1% and 93.4% (hazard ratio for death, 
0.86; 95% CI, 0.68 to 1.10) (Fig. 6). Death with-
out a preceding cancer-associated event was re-
ported in 4 patients assigned to receive exemestane 
plus ovarian suppression and in 8 patients as-
signed to receive tamoxifen plus ovarian suppres-
sion (Table S6 in the Supplementary Appendix).
Figure 5. Kaplan–Meier Estimates of Disease-free  
Survival, Freedom from Distant Recurrence, and Overall 
Survival in the Combined SOFT and TEXT Population.
Shown are estimates of disease‑free survival (Panel A), 
freedom from distant recurrence (Panel B), and overall 
survival (Panel C) among patients who received tamoxi‑
fen plus ovarian suppression (T–OS) and those who 
received exemestane plus ovarian suppression (E–OS) 
after a median follow‑up of 9 years in the combined 
population. In each panel, the 8‑year data are high‑
lighted by a black vertical line. The hazard ratio in 
Panel A is for disease recurrence, a second invasive 
cancer, or death. In Panels B and C, the hazard ratios 
are for distant recurrence of breast cancer and for 
death, respectively. The 8‑year values are based on 
 Kaplan–Meier estimates of the time to an event.
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 Treatment and Adverse Events
Early discontinuation of assigned oral endocrine 
therapy, with or without alternative therapy, oc-
curred in 22.5% of the tamoxifen group in SOFT, 
19.3% of the combined tamoxifen–ovarian sup-
pression group, and 23.7% of the combined ex-
emestane–ovarian suppression group (Tables S4 
and S8 in the Supplementary Appendix). The rate 
of early cessation of ovarian suppression by trip-
torelin without substitution of ovarian ablation 
was 19.0% in the combined population and was 
similar between the groups (Table S8 in the Sup-
plementary Appendix).
Targeted adverse events of grade 3 or higher 
were reported in 24.6% of the tamoxifen group 
in SOFT, 31.0% of the combined tamoxifen–ovar-
ian suppression group, and 32.3% of the combined 
exemestane–ovarian suppression group (Table 2). 
Thrombosis or embolism of any grade was re-
ported in 2.2% of the patients in the tamoxifen-
only group, in 2.3% of those in the tamoxifen–
ovarian suppression group, and in 1.2% of those 
in the exemestane–ovarian suppression group. 
Musculoskeletal symptoms of grade 3 or 4 oc-
curred in 6.7% of the patients in the tamoxifen 
group, in 5.7% of those in the combined tamox-
ifen–ovarian suppression group, and in 11.4% of 
those in the combined exemestane–ovarian sup-
Figure 6. Estimates of Disease-free Survival, Freedom from Distant Recurrence, and Overall Survival among Patients 
with HER2-Negative Disease in the Combined SOFT and TEXT Population.
Shown are hazard ratios and estimates of disease‑free survival, freedom from distant recurrence, and overall survival among patients 
with HER2‑negative breast cancer who received tamoxifen plus ovarian suppression (OS) and those who received exemestane plus 
ovarian suppression in the combined SOFT and TEXT population, according to receipt or nonreceipt of chemotherapy. The solid verti‑
cal lines at 0.70, 0.69, and 0.86 indicate the overall hazard‑ratio estimates for disease‑free survival (hazard ratio for disease recurrence, 
a second invasive cancer, or death), freedom from distant recurrence (hazard ratio for recurrence), and overall survival (hazard ratio for 
death), respectively, as calculated by means of Cox proportional‑hazards models. In the HER2‑negative population, inference from the 
treatment comparisons should be viewed as preliminary, since no testing was performed for heterogeneity of the treatment effects 
across cohorts. The 8‑year values are based on Kaplan–Meier estimates of the time to an event. The size of the squares is inversely pro‑
portional to the standard error of the hazard ratio. The median follow‑up was 9 years in the combined SOFT and TEXT population. The 
 results for patients with HER2‑positive disease are provided in Figure S10 in the Supplementary Appendix.
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pression group. Osteoporosis (defined as a T score 
of less than −2.5, which corresponds to a grade 
2, 3, or 4 adverse event) was reported in 3.9% of 
the patients in the tamoxifen group, in 7.2% of 
those in the combined tamoxifen–ovarian suppres-
sion group, and in 14.8% of those in the combined 
exemestane–ovarian suppression group. Vaginal 
dryness and dyspareunia were most frequent in 
the exemestane–ovarian suppression group. Hy-
pertension and glucose problems were more fre-
quent in the two ovarian-suppression groups than 
in the tamoxifen-only group.
Discussion
In the previously reported results of SOFT, we 
found that the addition of ovarian suppression 
to adjuvant tamoxifen did not result in a signifi-
Adverse Event
Tamoxifen 
(N = 1005)
Tamoxifen plus Ovarian 
Suppression 
(N = 2326)
Exemestane plus Ovarian 
Suppression 
(N = 2317)
Any Event
Grade 3 or 4 
Event Any Event
Grade 3 or 4 
Event Any Event
Grade 3 or 4 
Event
number of patients (percent)
Any targeted adverse event 962 (95.7) 247 (24.6) 2295 (98.7) 721 (31.0) 2288 (98.7) 748 (32.3)
Allergic reaction or hypersensitivity 35 (3.5) 2 (0.2) 110 (4.7) 9 (0.4) 122 (5.3) 12 (0.5)
Injection‑site reaction 4 (0.4) 0 189 (8.1) 1 (<0.1) 174 (7.5) 1 (<0.1)
Hot flushes 808 (80.4) 78 (7.8) 2175 (93.5) 284 (12.2) 2141 (92.4) 234 (10.1)
Depression 476 (47.4) 41 (4.1) 1195 (51.4) 108 (4.6) 1197 (51.7) 95 (4.1)
Sweating 492 (49.0) NA 1391 (59.8) NA 1286 (55.5) NA
Insomnia 470 (46.8) 30 (3.0) 1383 (59.5) 105 (4.5) 1375 (59.3) 89 (3.8)
Fatigue 612 (60.9) 34 (3.4) 1496 (64.3) 70 (3.0) 1450 (62.6) 75 (3.2)
Hypertension 181 (18.0) 57 (5.7) 550 (23.6) 188 (8.1) 564 (24.3) 168 (7.3)
Cardiac ischemia or infarction† 5 (0.5) 4 (0.4) 10 (0.4) 6 (0.3) 17 (0.7) 7 (0.3)
Thrombosis or embolism 22 (2.2) 17 (1.7) 53 (2.3) 47 (2.0) 27 (1.2) 20 (0.9)
Nausea 241 (24.0) 0 692 (29.8) 14 (0.6) 747 (32.2) 17 (0.7)
Musculoskeletal symptom 703 (70.0) 67 (6.7) 1809 (77.8) 132 (5.7) 2082 (89.9) 263 (11.4)
Osteoporosis 138 (13.7) 1 (0.1) 648 (27.9) 7 (0.3) 977 (42.2) 10 (0.4)
Fracture 53 (5.3) 8 (0.8) 140 (6.0) 23 (1.0) 179 (7.7) 37 (1.6)
Vaginal dryness 426 (42.4) NA 1144 (49.2) NA 1245 (53.7) NA
Decreased libido 434 (43.2) NA 981 (42.2) NA 1056 (45.6) NA
Dyspareunia 242 (24.1) 16 (1.6) 636 (27.3) 35 (1.5) 733 (31.6) 56 (2.4)
Urinary incontinence 166 (16.5) 6 (0.6) 433 (18.6) 9 (0.4) 317 (13.7) 9 (0.4)
CNS cerebrovascular ischemia 6 (0.6) 4 (0.4) 10 (0.4) 7 (0.3) 6 (0.3) 5 (0.2)
CNS hemorrhage 15 (1.5) 0 26 (1.1) 2 (0.1) 19 (0.8) 1 (<0.1)
Glucose intolerance‡ 18 (1.8) 4 (0.4) 68 (2.9) 23 (1.0) 63 (2.7) 15 (0.6)
Hyperglycemia‡ 20 (2.0) 1 (0.1) 92 (4.0) 20 (0.9) 71 (3.1) 14 (0.6)
*  Data are for patients in the safety populations in SOFT and TEXT who initiated a protocol‑assigned treatment, including 1005 patients who 
were randomly assigned to receive tamoxifen in SOFT and 4643 patients who were randomly assigned to receive tamoxifen plus ovarian 
suppression (2326 patients) or exemestane plus ovarian suppression (2317 patients) in SOFT or TEXT. Data are missing for 4 patients (1 in 
the tamoxifen group and 3 in the tamoxifen–ovarian suppression group) who initiated treatment but withdrew consent within 1 month after 
randomization and for whom no adverse‑event data were submitted. The 22 targeted adverse events and other adverse events of grade 3 or 
higher were categorized according to the Common Terminology Criteria for Adverse Events, version 3.0.9 The 95% confidence intervals for the 
percentages are provided in Table S9 in the Supplementary Appendix. CNS denotes central nervous system, and NA not applicable.
†  One patient in the tamoxifen group in SOFT had grade 5 cardiac ischemia or infarction; no other grade 5 targeted adverse events were reported.
‡  Glucose intolerance (diabetes) and hyperglycemia were added as targeted adverse events in 2011 and therefore may be underreported.
Table 2. Targeted Adverse Events during Treatment.*
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cantly better rate of disease-free survival than 
tamoxifen alone after a median follow-up of 5.6 
years.6 However, our updated analysis after a me-
dian follow-up of 8 years showed significantly 
higher rates of disease-free and overall survival 
with the addition of ovarian suppression to tamox-
ifen than with tamoxifen alone. Tamoxifen plus 
ovarian suppression resulted in a 24% lower rela-
tive risk of recurrence, a second invasive cancer, 
or death than tamoxifen alone (P = 0.009), which 
translated into an absolute difference of 4.2 per-
centage points in the rate of disease-free survival 
at 8 years. Exemestane plus ovarian suppression 
resulted in an even higher rate of disease-free 
survival, with a difference of 7.0 percentage points 
as compared with tamoxifen alone.
Our updated combined analysis of data from 
SOFT and TEXT showed that after a median fol-
low-up of 9 years, treatment with exemestane plus 
ovarian suppression resulted in sustained and 
consistently higher rates of disease-free survival 
and freedom from distant recurrence than the 
rates with tamoxifen plus ovarian suppression. 
Among premenopausal women receiving ovarian 
suppression, the observed difference of 2.1 per-
centage points in freedom from distant recurrence 
at 8 years favoring an aromatase inhibitor over 
tamoxifen was similar to that observed in post-
menopausal women treated with 5 years of aro-
matase inhibitors as compared with tamoxifen.10
Given the side effects of ovarian suppression, 
the overall results of SOFT do not imply that this 
treatment should be prescribed for all premeno-
pausal women with hormone-receptor–positive 
early breast cancer. Although the relative treat-
ment effects were similar regardless of receipt or 
nonreceipt of chemotherapy, the absolute bene-
fits were larger in the cohort of patients who 
remained premenopausal after previous chemo-
therapy. These patients had higher-risk clinico-
pathological features, including a younger age 
(median, 40 years), which contributed to a higher 
risk of recurrence. In this cohort, the rate of dis-
ease-free survival observed with tamoxifen plus 
ovarian suppression was 5.3 percentage points 
higher than that with tamoxifen alone, and the 
rate was 9.0 percentage points higher with exemes-
tane plus ovarian suppression. Improvements in 
overall survival are now evident at 8 years in SOFT 
among the women who had received chemother-
apy and were assigned to receive ovarian suppres-
sion with either tamoxifen or exemestane, as 
compared with those assigned to receive tamox-
ifen alone.
Among the women receiving ovarian suppres-
sion, the benefits of exemestane over tamoxifen 
were also more clinically meaningful in those at 
increased risk for recurrence, with increased 
rates of disease-free survival among women who 
had received chemotherapy. Among the patients 
who received exemestane plus ovarian suppression 
in the chemotherapy cohorts, the rate of disease-
free survival was higher by 3.7 percentage points 
in SOFT and by 6.0 percentage points in TEXT 
than the rate with tamoxifen plus ovarian sup-
pression; the rates of freedom from distant re-
currence were higher by 2.5 percentage points 
and 3.6 percentage points, respectively. In the 
combined analysis of data from SOFT and TEXT 
involving all the women who had received ovarian 
suppression, no significant difference in 8-year 
overall survival emerged according to whether they 
were assigned to receive exemestane or tamoxi-
fen. Given the long natural history of breast can-
cer with hormone-receptor positivity, conclusions 
regarding overall survival remain premature.
The majority of patients in the two trials had 
HER2-negative tumors, and for these women, 
the largest absolute difference in SOFT was seen 
with exemestane plus ovarian suppression, as com-
pared with tamoxifen alone. In the SOFT HER2-
negative chemotherapy cohort, absolute differences 
of 11.2 percentage points in disease-free survival 
and of 6.0 percentage points in freedom from dis-
tant recurrence favoring exemestane plus ovarian 
suppression were observed at 8 years. In the com-
bined analysis of the HER2-negative population, 
the 8-year rates of freedom from distant recur-
rence were higher among patients assigned to 
receive exemestane plus ovarian suppression than 
among those assigned to receive tamoxifen plus 
ovarian suppression (by 7.0 percentage points 
in SOFT and by 5.0 percentage points in TEXT). 
Distant recurrence in a premenopausal woman 
has a great effect on her quality of life and on 
both personal and family fulfillment and is as-
sociated with a substantial economic burden.11 
A more consistent benefit for aromatase in-
hibitors than for tamoxifen was also seen in 
patients with HER2-negative cancers in a meta-
analysis of three randomized trials involving 
postmenopausal women that was conducted by 
the Translational Aromatase Inhibitor Overview 
Group, in which heterogeneous treatment effects 
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were observed in patients with HER2-positive 
cancers.12
Since randomization in SOFT began in 2003, 
not all the patients with HER2-positive cancers 
received HER2-targeted therapy (60.1%). Hetero-
geneity in the treatment effect was evident accord-
ing to HER2 status. In particular, as compared 
with women who had HER2-negative cancers, 
those with HER2-positive cancers in the SOFT 
chemotherapy cohort had greater benefit with 
tamoxifen plus ovarian suppression than tamox-
ifen alone and less benefit with exemestane plus 
ovarian suppression (Fig. 3, and Figs. S9 and 10 
in the Supplementary Appendix).
Among the patients who did not receive chemo-
therapy, distant recurrence was reported in 26 
patients (1.8%) in SOFT and 37 patients (3.5%) 
in TEXT after a median follow-up of 8 years and 
9 years, respectively. This cohort in SOFT had 
low-risk clinicopathological features and had a 
higher rate of freedom from breast cancer with 
exemestane–ovarian suppression than with tamox-
ifen alone (by 4.0 percentage points) (Fig. S3A in 
the Supplementary Appendix). However, since in-
tensification of adjuvant endocrine therapy was 
predominantly associated with lower risks of local, 
regional, and contralateral breast cancer events, 
tamoxifen alone remains an appropriate adjuvant 
therapy for these women. In TEXT, all the patients 
who had undergone randomization were assigned 
to receive ovarian suppression, and 20.7% of the 
TEXT cohort who did not receive chemotherapy 
had lymph-node–positive disease. The combined 
comparison of ovarian suppression plus either 
an aromatase inhibitor or tamoxifen in SOFT 
and TEXT differs from the results of the Aus-
trian Breast and Colorectal Cancer Study Group 
Trial 1213 in many ways; such differences may 
have partially resulted from the high percentage 
of patients in the Austrian trial (>85%) who did 
not receive chemotherapy (Table S10 in the Sup-
plementary Appendix).
Women who receive the diagnosis of hormone-
receptor–positive breast cancer before the age of 
35 years are at particular risk for recurrence.4,5,14,15 
On the basis of the primary findings in SOFT,6 
guidelines were revised to include recommenda-
tions for the use of ovarian suppression in this age 
group.16-18 The 8-year results in this age group in 
SOFT showed that the rate of freedom from dis-
tant recurrence was 82.4% with exemestane plus 
ovarian suppression, 77.5% with tamoxifen plus 
ovarian suppression, and 73.8% with tamoxifen 
alone (differences of 8.6 percentage points and 
3.7 percentage points, respectively) (Fig. S4 in the 
Supplementary Appendix).
Potential benefits from ovarian suppression 
and aromatase inhibitors must be weighed against 
increased rates of acute19,20 and late toxic effects. 
Population studies involving women undergoing 
premenopausal bilateral oophorectomy without 
estrogen replacement have shown increased rates 
of subsequent side effects, including depression, 
hyperlipidemia, cardiovascular disease, diabetes, 
osteoporosis, and death from any cause.21-23 Such 
side effects may be treated with various strate-
gies (e.g., the use of bisphosphonates to preserve 
bone density, which may also reduce cancer re-
currence13). The toxicity profiles of exemestane 
plus ovarian suppression as compared with tamox-
ifen plus ovarian suppression remain similar to 
those seen in postmenopausal women. A greater 
proportion of women who were assigned to re-
ceive exemestane plus ovarian suppression had 
early discontinuation of oral endocrine therapy 
than those assigned to receive tamoxifen plus ovar-
ian suppression (23.7% vs. 19.3%). In individual 
patients, clinicians are tasked with weighing 
side effects and the effect on quality of life19,20 
associated with intensifying endocrine therapy 
against the risks of nonadherence and recurrence 
and the expected absolute improvement24 in dis-
ease outcome.
Longer follow-up is planned for SOFT and 
TEXT, since data regarding survival and late ad-
verse events are immature. In randomized trials 
of adjuvant endocrine therapy, maximal separa-
tion of Kaplan–Meier curves for overall survival 
has typically occurred more than 10 years after 
randomization.1,2,25 In a recent study, distant re-
currences continued to occur in the follow-up 
period from 5 to 20 years after diagnosis.26 After 
a median follow-up of 8 years or 9 years, the ef-
fects of ovarian suppression and aromatase in-
hibitors may not yet be fully appreciated.
We conclude that adding ovarian suppression 
to tamoxifen resulted in significantly higher rates 
of disease-free survival among premenopausal 
women than the use of tamoxifen alone. Further 
improvement was seen with exemestane plus ovar-
ian suppression. For patients who have HER2-
negative cancers and are at increased risk for 
recurrence, the absolute benefits of exemestane 
plus ovarian suppression in reducing recurrence 
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(particularly distant recurrence) make this com-
bination worthy of use in clinical practice. In 
women who were deemed to be at sufficient risk 
for recurrence to receive adjuvant chemotherapy 
and who retained premenopausal estradiol sta-
tus after chemotherapy, ovarian suppression re-
sulted in clinically meaningful improvements in 
disease-free survival. Such patients who received 
ovarian suppression plus either tamoxifen or 
exemestane had higher rates of overall survival 
at 8 years than those who received tamoxifen 
alone.
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